Maxime Jouaud
Chief Executive Officer
Major shareholder and member
of the strategic committee
Doctor in Neurosciences and Master 2 in Management and Business Administration.
Maxime is in charge of business development and representation of the company to the different public and private actors that gravitate around InSiliBio.
Benjamin Chantemargue
Scientific Director
Shareholder and member
of the strategic committee
Doctor in molecular modeling from the University of Limoges and Ph.D. in theoretical chemistry from the University of Palacky in the Czech Republic.
Benjamin is the scientific director of InSiliBio. His skills allow him to lead InSiliBio’s internal research team and to design R&D programs in collaboration with customers.
Mehdi Benmameri
R&D Engineer
Doctor in Computational Chemistry,
Master 1 and 2 Drug Design and Doctor of Pharmacy.
Mehdi is involved in the realization of the research projects by using molecular modeling techniques. Mehdi is involved in the use of molecular modeling techniques. (molecular dynamics, development of adapted computer tools to provide an adequate analysis and a reliable description of the studied molecular process)
Ágota Tóth
R&D Engineer
Doctor in Computational Chemistry, MSc, PhD in Medical Biotechnology
Ágota is working on the realization of different research projects by using molecular modeling techniques, such as molecular dynamics and docking. Ágota is involved in the development of computational tools to adequately describe the studied molecular processes.
Marving Martin
PhD student, CIFRE
Doctor in Pharmacy (Limoges) and Master in Drug Design In Silico (Paris).
Marving is in charge of the research and development of the company’s new « InSiliSkin » service through a university research thesis in partnership with the INSERM P&T laboratory in Limoges.
The shareholders have allowed InSiliBio to start a strong growth thanks to an important initial capital. Now they have the power to vote on significant issues such as approving strategic decisions. Their input and feedback can be valuable in shaping the direction of the company and ensuring that it remains focused on achieving its goals.
Pr Patrick Trouillas
Patrick is a Professor at the University of Limoges (Faculty of Pharmacy). He has been working for more than 20 years at developing of the physical chemical methodologies currently used within InSiliBio. He is the co-founder and the president of the strategic committee of InSiliBio.
Pr Michal Otyepka
Michal is a Professor at the CATRIN Research Institute in Czech Republic (Olomouc). He is the head of CATRIN-RCPTM laboratory and he has been Patrick’s sidekick for years. Together, they bring their scientific expertise and network to InSiliBio.
Jouaud Investissement
The holding company was an important financial support for the creation of the company and today its president accompanies us in the commercial development and the structuring of the company.